In conclusion, our results demonstrate that Chel A's anti-cancer activities are achieved by down-regulating PHLPP2 via protein degradation, subsequently increasing the phosphorylation of c-Jun accumulation, and cancer cell apoptosis, as well as anchorage-independent growth retardation as diagramed in Figure 5H. This evidence concerns the gene PHLPP2 and cancer.